07:00 , Sep 5, 2005 |  BC Week In Review  |  Clinical News

ACP-SL017: Phase I start

AAF will begin an open-label, dose-escalation, Phase I trial in patients to evaluate ACP-SL017 with and without photoactivation. The company expects to complete the trial before the year end. Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Company News

Altachem management update

Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta   Business: Infectious, Cancer   Resigned: Warren Jackson as EVP of international business   ...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

Altachem board of directors update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta   Business: Infectious, Cancer   Resigned: Robert Sydenham and Warren Jackson   Appointed: Ragupathy Madiyalakan, a director, as chairman   ...
07:00 , Aug 9, 2004 |  BC Week In Review  |  Company News

Isotechnika Inc., Altachem deal

ISA acquired AAF's breath kit manufacturing business for C$500,000 (US$376,150). ISA paid C$300,000 up front and will pay the remaining C$200,000 in the form of royalties on kits produced. AAF had been ISA's exclusive manufacturer...
08:00 , Jan 6, 2003 |  BC Week In Review  |  Company News

Altachem management update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta   Business: Infectious diseases, Cancer   Resigned: Madi Madiyalakan as EVP of R&D   ...
08:00 , Jan 6, 2003 |  BC Week In Review  |  Company News

Altachem board of directors update

Altachem Pharma Ltd. (TSE:AAF), Edmonton, Alberta   Business: Infectious diseases, Cancer   Resigned: Madi Madiyalakan   ...
08:00 , Apr 1, 2002 |  BC Week In Review  |  Clinical News

Altachem preclinical data

Hypocrellin compounds activated using ultrasound delayed tumor growth in mice and in human leukemia in culture. Data were presented at the Symposium on Sonodynamic Therapy in Fukuoka. Altachem Pharma Ltd. (CDNX:AAF), Edmonton, Alberta   Product: Ultrasound-activated...
08:00 , Mar 25, 2002 |  BC Week In Review  |  Company News

Altachem deal

AAF purchased from an undisclosed party exclusive rights to an immunomodulator for 400,000 AAF shares valued at C$920,000 (US$580,980) based on AAF’s Friday close at C$2.30. AAF plans to use the preclinical product alone and...
07:00 , Apr 19, 1999 |  BC Week In Review  |  Company News

Steroidogenesis Inhibitors International, Altachem-Pharma Ltd. deal

STGI received a $50,000 license payment from AAF for the use of STGI's Anticort procaine anti-cortisol immune booster to treat HIV in Canada. The payment brings the final total of license fees that STGI has...
07:00 , Apr 12, 1999 |  BC Week In Review  |  Clinical News

Anticort procaine: Began Phase I testing

Steroidogenesis Inhibitors International (STGI), Las Vegas, Nev.   Product: Anticort procaine   Business: Infectious diseases   Therapeutic category: Immune stimulation   Target: Cortisol   Description: Procaine anti-cortisol immune booster   Indication: Treat HIV infection/AIDS   Status: Altachem Pharma Ltd. (ASE:AAF, Edmonton,...